Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Total Current Liabilities: 2016-2025

Historic Total Current Liabilities for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $156.8 million.

  • Tg Therapeutics' Total Current Liabilities rose 25.33% to $156.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.8 million, marking a year-over-year increase of 25.33%. This contributed to the annual value of $90.7 million for FY2024, which is 68.80% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Total Current Liabilities is $156.8 million, which was down 8.77% from $171.9 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Total Current Liabilities ranged from a high of $171.9 million in Q2 2025 and a low of $36.4 million during Q3 2022.
  • For the 3-year period, Tg Therapeutics' Total Current Liabilities averaged around $105.5 million, with its median value being $99.7 million (2024).
  • Per our database at Business Quant, Tg Therapeutics' Total Current Liabilities slumped by 58.42% in 2022 and then spiked by 116.92% in 2024.
  • Tg Therapeutics' Total Current Liabilities (Quarterly) stood at $65.4 million in 2021, then dropped by 18.63% to $53.2 million in 2022, then rose by 0.98% to $53.7 million in 2023, then soared by 68.80% to $90.7 million in 2024, then climbed by 25.33% to $156.8 million in 2025.
  • Its Total Current Liabilities stands at $156.8 million for Q3 2025, versus $171.9 million for Q2 2025 and $160.2 million for Q1 2025.